Peptide Biologix
Compound index
The atlas

LL-37: Cathelicidin Antimicrobial Peptide

LL-37 is the sole human cathelicidin antimicrobial peptide — a 37-amino acid cationic amphipathic α-helical host defense peptide cleaved by proteinase 3 from the C-terminus of the 18 kDa precursor protein hCAP18 (encoded by the vitamin D-regulated CAMP gene). It combines broad-spectrum membrane-disruptive bactericidal, antiviral, and anti-biofilm activity with chemotactic signaling via FPR2 (FPRL1), EGFR transactivation, and lipopolysaccharide neutralization.

Detailed natural-history study of a branching green-grey lichen rosette
Plate 18LL-37
Primary Structure (37-Residue Amphipathic α-Helical Cathelicidin) LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
Regulatory & Compounding Status (Updated April 22, 2026)

LL-37 is an unapproved investigational peptide and has not been approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for any clinical indication. FDA's page current as of April 22, 2026 lists LL-37 as nominated but withdrawn. Withdrawal is not approval or clearance. All data in this monograph are presented strictly for laboratory and educational reference.

1. Overview and Classification

LL-37 is a 37-amino acid cationic antimicrobial peptide that represents the sole human member of the cathelicidin family of host defense peptides. Derived from the C-terminal region of the human cationic antimicrobial protein 18 (hCAP18), LL-37 takes its name from its two N-terminal leucine residues and total length of 37 amino acids [Gudmundsson et al., 1996]. This multifunctional peptide serves as a critical component of the human innate immune system, exhibiting broad-spectrum antimicrobial activity alongside diverse immunomodulatory, wound healing, and chemotactic properties.

Unlike conventional antibiotics that target specific metabolic pathways, LL-37 operates primarily through physical disruption of microbial membranes while simultaneously orchestrating host immune responses. The peptide is constitutively expressed in neutrophils, where it is stored as the inactive precursor hCAP18 in specific granules, and is inducibly expressed in epithelial cells lining barrier tissues including skin, respiratory tract, gastrointestinal tract, and urogenital system. Expression is regulated by multiple factors, notably 1,25-dihydroxyvitamin D3 through a vitamin D response element (VDRE) in the CAMP gene promoter [Gombart et al., 2005].

In biomedical research, LL-37 has garnered substantial interest across multiple therapeutic domains: infectious disease (antibiotic-resistant bacteria, viral infections, biofilm disruption), dermatology (wound healing, psoriasis, rosacea, atopic dermatitis), oncology (context-dependent tumor suppression or promotion), and autoimmune disorders. Over 2,000 peer-reviewed publications have investigated LL-37's structure, mechanisms, physiological roles, and therapeutic potential since its discovery in the mid-1990s.

2. Molecular Structure, Synthesis, and Chemical Properties

2.1 Primary Structure and Sequence Analysis

LL-37 consists of 37 amino acid residues with the single-letter sequence: LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES. The complete three-letter sequence is: Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser. The peptide is encoded by the CAMP (cathelicidin antimicrobial peptide) gene located on chromosome 3p21.3, which produces the 18 kDa proprotein hCAP18 consisting of an N-terminal signal peptide, a conserved cathelin domain, and the C-terminal LL-37 domain (37 residues).

Proteolytic cleavage of hCAP18 by proteinase 3 in neutrophils or kallikreins in epithelial tissues liberates the active LL-37 peptide. In skin and sweat, further proteolytic processing by kallikrein 5 and kallikrein 7 generates shorter antimicrobial fragments, which exhibit distinct antimicrobial spectra and reduced immunomodulatory activity compared to full-length LL-37.

Table 1: Molecular Specifications of LL-37
Parameter Value / Specification
Primary Sequence LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
Molecular Formula C205H340N60O53
Molecular Weight 4493.33 g/mol (4493.3 Da)
CAS Registry Number 154947-66-7
Amino Acid Length 37 residues
Net Charge at pH 7.0 +6 (11 basic residues: 6 Lys, 5 Arg; 5 acidic residues: 3 Glu, 2 Asp)
Isoelectric Point (pI) 10.5 (theoretical)
Hydrophobic Content 45.9% hydrophobic residues
Secondary Structure Amphipathic α-helix (residues 2–31, 50–70% helicity in membrane-mimetic environments)
Precursor Protein hCAP18 (170 residues, 18 kDa), encoded by CAMP gene (chromosome 3p21.3)

2.2 Secondary and Tertiary Structure

In dilute aqueous solutions at low ionic strength, LL-37 exists predominantly as a disordered random coil. Upon exposure to physiologically relevant salt concentrations, higher peptide concentrations, lipopolysaccharides (LPS), or lipid bilayers, LL-37 undergoes a pronounced conformational transition to an amphipathic α-helical structure [Oren et al., 1999]. High-resolution NMR spectroscopy in sodium dodecyl sulfate (SDS) or dodecylphosphocholine (DPC) micelles demonstrates a curved α-helix spanning residues 2–31, with a disordered C-terminal tail (residues 32–37) containing a helix-breaking proline at position 33.

The amphipathic α-helix segregates hydrophobic residues (Leu, Ile, Phe, Val) onto the concave face and positively charged residues (Lys, Arg) onto the convex hydrophilic face. A slight bend occurs near Gly14, dividing the helix into an N-terminal domain (residues 2–12) involved in oligomerization, a central core (residues 13–31) essential for antimicrobial and membrane-lytic activity, and the flexible C-terminal tail (residues 32–37).

2.3 Physicochemical and Solution Properties

With 11 basic residues (6 lysines and 5 arginines) and 5 acidic residues (3 glutamates and 2 aspartates), LL-37 carries a net charge of +6 at physiological pH (7.4) and a theoretical isoelectric point (pI) of 10.5. This strong cationic character drives electrostatic attraction to negatively charged bacterial membrane components such as lipopolysaccharide (LPS) in Gram-negative bacteria and lipoteichoic acid (LTA) or phosphatidylglycerol in Gram-positive bacteria.

In aqueous solution, LL-37 exhibits concentration- and salt-dependent self-association (oligomerization) into dimers, tetramers, and higher-order fibrillar bundles driven by hydrophobic interactions along the non-polar face of the α-helix [Oren et al., 1999]. While oligomerization protects the peptide from rapid proteolytic cleavage in biological fluids, excessive aggregation during storage or handling can reduce apparent in vitro monomeric bioactivity.

2.4 Solid-Phase Synthesis vs. Recombinant Production Methods

In addition to Fmoc solid-phase peptide synthesis (SPPS), LL-37 can be produced recombinantly in bacterial expression systems such as Escherichia coli. However, because free LL-37 is directly bactericidal toward the expression host, recombinant production requires fusing the peptide to carrier proteins or expressing it as insoluble inclusion bodies followed by refolding. Common carrier strategies include glutathione S-transferase (GST), maltose-binding protein (MBP), or small ubiquitin-like modifier (SUMO) fusions that neutralize antimicrobial toxicity during fermentation and facilitate affinity capture. Following purification of the fusion protein, site-specific proteases (thrombin, Factor Xa, or SUMO protease) cleave the carrier tag to liberate native LL-37, which then undergoes orthogonal RP-HPLC polishing to remove the cleaved tag, residual uncleaved fusion protein, and protease. While recombinant expression is scalable for bulk manufacturing, Fmoc-SPPS remains the predominant route for research-grade LL-37 due to its direct sequence control, absence of bacterial host-protein carryover, and high chromatographic recovery.

3. Mechanisms of Action

3.1 Direct Antimicrobial Activity and Membrane Disruption

LL-37's primary antimicrobial mechanism involves electrostatic binding to anionic microbial membranes followed by insertion of its amphipathic α-helical structure into the lipid bilayer interface. Unlike classical barrel-stave pore formers, solid-state NMR studies demonstrate that LL-37 aligns parallel to the membrane surface in a carpet-like orientation at low peptide-to-lipid ratios, and induces positive membrane curvature strain above a threshold concentration to form toroidal pores [Oren et al., 1999]. Membrane permeabilization causes rapid dissipation of transmembrane electrochemical gradients, leakage of cytoplasmic ATP and ions, and bacterial cell death within minutes.

Selectivity for microbial over mammalian membranes arises from fundamental differences in lipid composition: bacterial outer leaflets are enriched in negatively charged phospholipids (phosphatidylglycerol, cardiolipin), whereas mammalian plasma membrane outer leaflets consist primarily of zwitterionic phospholipids (phosphatidylcholine, sphingomyelin) and cholesterol, which increases bilayer rigidity and inhibits peptide insertion. Physiological serum proteins (such as apolipoprotein A-I) bind LL-37 and attenuate host cell toxicity in vivo.

Table 2: Antimicrobial Activity of LL-37 Against Selected Pathogens
Pathogen MIC Range (μg/mL) Clinical & Experimental Relevance Reference
Escherichia coli 2–16 UTI, sepsis, gastrointestinal infections Oren et al., 1999 [PMID: 15703214]
Pseudomonas aeruginosa 4–32 Wound infections, pneumonia, biofilm inhibition Overhage et al., 2008 [PMID: 11932229]
Staphylococcus aureus (MSSA & MRSA) 4–32 Skin infections, pneumonia, drug-resistant infections Overhage et al., 2008 [PMID: 11932229]
Streptococcus pneumoniae 2–8 Pneumonia, meningitis, otitis media Dürr et al., 2006 [PMID: 16814439]
Klebsiella pneumoniae & Acinetobacter baumannii 4–32 Hospital-acquired and multidrug-resistant infections Overhage et al., 2008 [PMID: 11932229]
Mycobacterium tuberculosis 32–64 Tuberculosis and alveolar epithelial host defense Rivas-Santiago et al., 2008 [PMID: 18667697]

Beyond planktonic bactericidal activity, LL-37 inhibits bacterial biofilm formation at sub-inhibitory concentrations by downregulating quorum-sensing genes, stimulating twitching motility, and preventing initial surface attachment [Overhage et al., 2008]. Against enveloped viruses such as Influenza A, LL-37 directly disrupts the viral lipid envelope and modulates host airway inflammatory responses [Barlow et al., 2006].

3.2 Receptor-Mediated Immunomodulatory Signaling

LL-37 acts as an endogenous alarmin that bridges innate and adaptive immunity through specific host cell surface and intracellular receptors [Vandamme et al., 2012]:

  • Formyl Peptide Receptor 2 (FPR2 / FPRL1): LL-37 binds the Gi-protein-coupled receptor FPRL1 on neutrophils, monocytes, CD4+ T cells, and mast cells, inducing directed chemotaxis, calcium mobilization, and angiogenesis [Yang et al., 2000].
  • Epidermal Growth Factor Receptor (EGFR) Transactivation: In airway epithelial cells and keratinocytes, LL-37 activates metalloproteinase-mediated cleavage of membrane-anchored EGFR ligands, inducing EGFR phosphorylation, MAPK/ERK1/2 and PI3K/Akt activation, and epithelial cell migration for wound re-epithelialization [Tjabringa et al., 2003].
  • Endotoxin (LPS) Neutralization & TLR Modulation: Through high-affinity electrostatic and hydrophobic binding to Gram-negative bacterial lipopolysaccharide (LPS) and Gram-positive lipoteichoic acid (LTA), LL-37 suppresses excessive TLR-mediated pro-inflammatory TNF-α and IL-1β release in endotoxemia models. Conversely, LL-37 can complex with extracellular self-nucleic acids in autoimmune dermatoses such as psoriasis.

3.3 Vitamin D Regulation and Innate Host Defense

A landmark discovery in human innate immunity revealed that the human CAMP gene promoter contains a consensus vitamin D response element (VDRE) bound by the vitamin D receptor (VDR) upon activation by 1,25-dihydroxyvitamin D3 [Gombart et al., 2005]. Active vitamin D signaling strongly upregulates LL-37 transcription in human myeloid and epithelial cells, linking systemic vitamin D status to mucosal and macrophage antimicrobial defense alongside human β-defensin expression during Mycobacterium tuberculosis infection of alveolar epithelial cells [Rivas-Santiago et al., 2008].

4. Physiological Expression and Proteolytic Metabolism

4.1 Endogenous Expression in Human Health and Disease

Expression studies in healthy individuals have documented constitutive LL-37 production by neutrophils and inducible expression by epithelial cells of the skin and mucosal surfaces. Plasma concentrations in healthy adults typically range from 1 to 5 μg/mL, while local concentrations at sites of inflammation or injury can reach significantly higher levels. Clinical biomarker studies have identified altered LL-37 levels across multiple dermatological and infectious conditions: patients with atopic dermatitis exhibit reduced LL-37 expression in affected skin (correlating with increased susceptibility to Staphylococcus aureus colonization), whereas patients with psoriasis and rosacea display elevated lesional LL-37 levels that contribute to cutaneous inflammatory signaling.

4.2 Proteolytic Degradation and Clearance

Exogenously administered unmodified LL-37 is susceptible to proteolytic cleavage by both host and microbial proteases, including serine proteases, mast cell tryptase, neutrophil elastase, and bacterial metalloproteinases (such as Pseudomonas aeruginosa elastase and Staphylococcus aureus aureolysin). In human plasma, binding to apolipoprotein A-I (apoA-I) partially shields LL-37 from immediate proteolysis while sequestering its free membrane-lytic fraction.

5. Preclinical and Clinical Research Evidence

5.1 Infectious Disease and Biofilm Models

In influenza virus models, LL-37 reduces viral replication, decreases viral titers in infected lungs, and improves survival in lethal infection challenges when administered intranasally, exhibiting both direct virucidal activity against influenza virus particles and immunomodulatory attenuation of host lung immunopathology [Barlow et al., 2006]. Similar antiviral activity has been demonstrated against respiratory syncytial virus (RSV), herpes simplex virus (HSV), HIV, and vaccinia virus in vitro and in animal models.

In bacterial biofilm models infected with Pseudomonas aeruginosa or MRSA, local LL-37 application disrupts the extracellular polymeric matrix, inhibits biofilm attachment, and enhances the susceptibility of biofilm-embedded bacteria to conventional antibiotics [Overhage et al., 2008].

5.2 Wound Healing and Cutaneous Regeneration

In murine excisional, burn, corneal, and diabetic wound models, topical LL-37 application accelerates wound closure, enhances keratinocyte migration and re-epithelialization via EGFR transactivation, stimulates angiogenesis, and improves granulation tissue formation [Tjabringa et al., 2003]. Diabetic wounds typically exhibit reduced endogenous cathelicidin expression, and replacement with exogenous LL-37 partially restores healing capacity. In clinical translation, a Phase I/II trial evaluated a topical formulation of LL-37 for venous leg ulcers, demonstrating safety, local tolerability, and preliminary evidence of enhanced healing, though larger controlled trials are needed to confirm efficacy.

5.3 Inflammatory Bowel Disease, Autoimmune, and Oncology Models

LL-37 exhibits pronounced context-dependent pleiotropy across inflammatory, autoimmune, and neoplastic models [Vandamme et al., 2012]:

  • Sepsis & Endotoxemia: In murine sepsis models, LL-37 administration reduces mortality, decreases pro-inflammatory cytokine levels, and limits organ damage through LPS-neutralizing and immunomodulatory mechanisms.
  • Inflammatory Bowel Disease (IBD) Models: In preclinical IBD models, LL-37's effects are complex and context-dependent: while the peptide provides protection in some experimental colitis models through antimicrobial defense and mucosal barrier protection, aberrant LL-37 expression has been implicated in certain IBD phenotypes.
  • Autoimmune Dermatoses: Whereas atopic dermatitis lesions show deficiency of LL-37, psoriatic and systemic lupus erythematosus (SLE) models show that excessive LL-37 can complex with extracellular self-nucleic acids to drive plasmacytoid dendritic cell activation.
  • Context-Dependent Oncology Effects: Direct cytotoxic and tumor-suppressive effects have been observed in gastric and colon cancer models, whereas in ovarian, breast, and lung cancer models, elevated stromal LL-37 has been associated with angiogenesis, epithelial-mesenchymal transition (EMT), and tumor progression.
Table 3: Summary of Major Preclinical and Clinical Research Studies on LL-37
Research Domain Experimental Model / Study Principal Findings
Discovery & Processing Human neutrophil granules [Gudmundsson et al., 1996] Identified FALL-39/LL-37 as the 37-aa C-terminal antimicrobial peptide processed from hCAP18
Membrane Biophysics Phospholipid bilayers & NMR [Oren et al., 1999]; [Dürr et al., 2006] Demonstrated concentration-dependent oligomerization, amphipathic α-helix (residues 2–31), and toroidal pore mechanism
Immune Chemotaxis Human leukocytes [Yang et al., 2000] Established FPRL1 (FPR2) as the chemotactic receptor for LL-37 on neutrophils, monocytes, and T cells
Epithelial Activation Airway epithelial cells [Tjabringa et al., 2003] Demonstrated metalloproteinase-dependent transactivation of EGFR and downstream ERK1/2 signaling
Vitamin D Axis Human myeloid & epithelial cells [Gombart et al., 2005] Identified direct VDR binding to the CAMP promoter VDRE and strong upregulation by 1,25(OH)2D3
Antiviral Defense Murine Influenza A infection [Barlow et al., 2006] Reduced lung viral replication, blunted inflammatory cytokines, and enhanced survival
Biofilm Inhibition Pseudomonas aeruginosa biofilms [Overhage et al., 2008] Inhibited biofilm formation
Venous Leg Ulcers Phase I/II clinical trial Demonstrated local safety, tolerability, and preliminary healing benefits in chronic venous ulcers

6. Analytical Verification and Quality Control

6.1 Solid-Phase Synthesis and Identity Confirmation

Research-grade LL-37 is synthesized via Fmoc solid-phase peptide synthesis (SPPS). Because assembling a 37-residue amphipathic sequence is prone to on-resin aggregation, rigorous quality control is essential to separate single-amino-acid deletion peptides and minor oxidation or deamidation species.

Electrospray ionization mass spectrometry (ESI-MS) or MALDI-TOF MS confirms molecular weight (4493.3 ± 2.0 Da), while tandem MS/MS sequencing verifies the intact 37-mer sequence. Reversed-phase HPLC on C18 or C8 columns using a water/acetonitrile/0.1% trifluoroacetic acid (TFA) gradient with UV detection at 214–220 nm verifies purity (≥95.0% main peak area).

Table 4: Analytical Quality Control Specifications for Research-Grade LL-37
Analytical Test Method Acceptance Specification
Chemical Purity RP-HPLC (C18/C8 column, 214–220 nm UV detection) ≥95.0% main peak; related substances <3%
Molecular Mass Identity ESI-MS or MALDI-TOF MS 4493.3 ± 2.0 Da
Secondary Structure Far-UV Circular Dichroism (CD) in TFE or SDS micelles Characteristic α-helical double minima at 208 nm and 222 nm (50–70% helicity)
Sequence Verification MS/MS Fragmentation & Amino Acid Analysis 100% sequence match; all amino acids within ±15% of theoretical
Water & Counterion Content Karl Fischer Titration & Ion Chromatography Water ≤10.0%; TFA content ≤1.0% (or acetate salt conversion)
Endotoxin Level Limulus Amebocyte Lysate (LAL) Assay ≤10 EU/mg (<0.1 EU/mg preferred for macrophage/TLR signaling assays)
Functional Bioassay Microdilution MIC Assay (E. coli ATCC 25922) MIC 2–16 μg/mL (or ≤10 μg/mL reference specification)

6.2 Endotoxin Contamination and Counterion Considerations

Because LL-37 binds bacterial lipopolysaccharide with high affinity, trace endotoxin contamination introduced during synthesis or lyophilization remains complexed to the peptide and can confound macrophage, dendritic cell, or TLR signaling assays. Researchers investigating immunomodulatory pathways should verify LAL endotoxin levels and consider acetate counterion preparations over trifluoroacetate (TFA) salts when working with sensitive primary cell cultures. Complementary characterization workflows apply to other immune peptides such as Thymosin Alpha-1.

7. Research Applications and Experimental Protocols

7.1 In Vitro and Preclinical Dosing Paradigms

In laboratory research, LL-37 is used as a reference standard for antimicrobial peptide susceptibility assays, biofilm dispersal studies, FPR2/EGFR receptor signaling, and vitamin D-mediated innate immunity. Importantly, high physiological salt concentrations can reduce direct antimicrobial activity in vitro through electrostatic shielding, whereas immunomodulatory functions are preserved under physiological salt conditions. Parallel immunomodulatory and tissue-repair investigations often compare LL-37 with Thymosin Beta-4 and GHK-Cu.

Table 5: Representative In Vitro and Preclinical Animal Research Protocols Literature summary of published study doses, routes, and schedules.
Experimental Application Concentration / Dose Range Methodological Notes
Antimicrobial Assays (In Vitro) 0.1–100 μg/mL (0.02–22 μM) Broth microdilution MIC and time-kill kinetics (sensitive to ionic strength and serum)
Biofilm Prevention (In Vitro) 0.5–10 μg/mL Sub-MIC inhibition of P. aeruginosa and S. aureus attachment and quorum sensing
Leukocyte Chemotaxis & Immunomodulation 1–50 μg/mL (0.2–11 μM) FPR2 chemotaxis, LPS neutralization, and cytokine modulation
Keratinocyte Migration (In Vitro) 2–10 μg/mL EGFR transactivation and scratch-wound closure without cytotoxicity
Topical Wound Models (Rodent In Vivo) 10–100 μg per wound Topical application in preclinical wound models
Intranasal / Pulmonary Models (Mouse) 1–10 μg per dose (0.05–0.5 mg/kg) Influenza A, RSV, or P. aeruginosa respiratory challenge models
Systemic Sepsis Models (Mouse IP/SC) 0.1–10 mg/kg Endotoxemia (LPS challenge) and polymicrobial sepsis survival studies

8. Storage and Handling Protocols

Because LL-37 is an amphipathic peptide prone to concentration- and agitation-induced self-assembly and surface adsorption, careful laboratory handling is essential. Reconstitution solvent should be added gently down the inner wall of the vial and dissolved by slow swirling or inversion — never vigorous vortexing, which promotes irreversible fibrillar aggregation at the air-water interface. Polypropylene low-protein-binding microcentrifuge tubes are strongly recommended to minimize adsorptive loss from dilute working solutions.

Table 6: Storage and Stability Guidelines for LL-37
Form Storage Condition Typical Stability Period Laboratory Handling Notes
Lyophilized Powder (Unopened) −20°C freezer, desiccated 24–36 months Equilibrate sealed vial to room temperature before opening to prevent moisture condensation
Lyophilized Powder (Short-Term) 2–8°C refrigerator 6–12 months Protect from light and humidity
Reconstituted Unbuffered Aqueous Solution 2–8°C refrigerator 3–7 days Prepare at 1–5 mg/mL; avoid vortexing
Reconstituted Buffered Solution (pH 6.0–7.4) 2–8°C refrigerator 7–14 days High salt (≥150 mM NaCl) induces α-helical oligomerization
Frozen Single-Use Aliquots −80°C ultra-low freezer 6–12 months Use low-binding polypropylene tubes; strictly avoid repeated freeze-thaw cycles

9. Safety Profile, Cytotoxicity, and Research Limitations

While topical and low-concentration local applications of LL-37 have demonstrated favorable tolerability in preclinical models and early-phase venous ulcer trials, several critical biological and toxicological considerations govern its research profile:

  • Concentration-Dependent Eukaryotic Cytotoxicity: At low micromolar concentrations (1–10 μg/mL), LL-37 promotes epithelial survival and migration; however, at higher concentrations (particularly in serum-free media), its non-selective membrane-permeabilizing activity can induce eukaryotic cell lysis and apoptosis.
  • Autoimmune Nucleic Acid Sensing: By forming protease-resistant complexes with extracellular self-DNA and self-RNA that activate endosomal TLR9/TLR7 in plasmacytoid dendritic cells, exogenous LL-37 can exacerbate type I interferon-driven autoimmune pathologies such as psoriasis, systemic lupus erythematosus (SLE), and rosacea.
  • Dual Roles in Neoplasia: Because LL-37 transactivates EGFR/ErbB2 and stimulates FPR2-dependent angiogenesis, its effects in oncology models are highly tissue-dependent, suppressing gastric and colon carcinoma growth while promoting ovarian, breast, and lung tumor progression in preclinical models.

10. Primary Literature References

  1. Gudmundsson GH, et al. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem. 1996;238(2):325-332.
  2. Oren Z, et al. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochem J. 1999;341(Pt 3):501-513.
  3. Yang D, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med. 2000;192(7):1069-1074.
  4. Tjabringa GS, et al. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J Immunol. 2003;171(12):6690-6696.
  5. Gombart AF, et al. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005;19(9):1067-1077.
  6. Barlow PG, et al. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One. 2006;1:e96.
  7. Overhage J, et al. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun. 2008;76(9):4176-4182.
  8. Dürr UH, et al. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta. 2006;1758(9):1408-1425.
  9. Rivas-Santiago B, et al. Human β-defensin 2 is expressed and associated with Mycobacterium tuberculosis during infection of human alveolar epithelial cells. Infect Immun. 2008;76(9):4218-4227.
  10. Vandamme D, et al. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. 2012;280(1):22-35.